Exclusive Summary

• **Seizing the Multi-Billion Dollar Patent Cliff**: Targets a blockbuster prostate cancer therapy (e.g., Enzalutamide) with originator patents expiring ~2027, offering a prime window for 'Day-1 Launch' partnerships.
• **De-risked via Clinical Proof**: Touting 'Clinical in China' status serves as a robust validator of bioequivalence and safety, significantly lowering regulatory risks compared to competitors with only in-vitro data.
• **Cost-Efficient Licensing Model**: leverage China's integrated supply chain to offer a competitive Cost of Goods Sold (COGS), enabling partners to maximize margins in price-sensitive generic markets.

Asset Materials

Contact Us for Full Materials